Tyramine infusions and selective monoamine oxidase inhibitor treatment

1981 ◽  
Vol 74 (1) ◽  
pp. 4-7 ◽  
Author(s):  
David Pickar ◽  
Robert M. Cohen ◽  
David C. Jimerson ◽  
Dennis L. Murphy
Keyword(s):  
Monoamine Oxidase ◽  
Monoamine Oxidase Inhibitor ◽  
Oxidase Inhibitor ◽  
Inhibitor Treatment

Effects of chronic monoamine oxidase inhibitor treatment on biogenic amine metabolism in rat brain

1979 ◽  
Vol 18 (10) ◽  
pp. 771-776 ◽  
Author(s):  
D.S. Robinson ◽  
I.C. Campbell ◽  
Margaret Walker ◽  
Nancy J. Statham ◽  
W. Lovenberg ◽  
...  
Keyword(s):  
Monoamine Oxidase ◽  
Rat Brain ◽  
Biogenic Amine ◽  
Monoamine Oxidase Inhibitor ◽  
Oxidase Inhibitor ◽  
Amine Metabolism ◽  
Inhibitor Treatment

Tyramine infusions and selective monoamine oxidase inhibitor treatment

1981 ◽  
Vol 74 (1) ◽  
pp. 8-12 ◽  
Author(s):  
David Pickar ◽  
Robert M. Cohen ◽  
David C. Jimerson ◽  
C. Raymond Lake ◽  
Dennis L. Murphy
Keyword(s):  
Monoamine Oxidase ◽  
Monoamine Oxidase Inhibitor ◽  
Oxidase Inhibitor ◽  
Inhibitor Treatment

scholarly journals The inhibitory action of l-dihydroxyphenylalanine (l-dopa) in the presence of a monoamine oxidase inhibitor on protein synthesis in vivo and the partial amelioration of this by methionine supplementation

1980 ◽  
Vol 192 (2) ◽  
pp. 703-707 ◽  
Author(s):  
A H Bone ◽  
H R Taufek
Keyword(s):  
Protein Synthesis ◽  
Amino Acid ◽  
Monoamine Oxidase ◽  
Inhibitory Action ◽  
Monoamine Oxidase Inhibitor ◽  
Age Groups ◽  
Specific Radioactivity ◽  
Oxidase Inhibitor ◽  
Inhibitor Treatment

Male Wistar rats of various age groups were injected daily over a period of 3 weeks with iproniazid (10 micrograms/g body wt.) and L-dihydroxyphenylalanine (L-dopa; 0.1 mg/g body wt.). On the final day 1 h before the termination of the experiment the animals were injected with L-[14C]valine (0.1 microCi/g body wt.). The specific radioactivity of the valine in the proteins of the subcellular fractions of the tissues examined, relative to the time-integrated mean specific radioactivity of this amino acid in the acid-soluble pools of these tissues, was used to assess protein synthesis. The L-dopa/monoamine oxidase-inhibitor treatment was associated with 30–40% inhibition of protein synthesis. Supplementation of the dietary methionine intake by injection of this amino acid markedly diminished the inhibitory action of the L-dopa/monoamine oxidase-inhibitor treatment on protein synthesis in all fractions examined.

Current issues in monoamine oxidase inhibitor treatment

1990 ◽  
Vol 7 (2) ◽  
pp. 159-167
Author(s):  
Sinead O'Brien ◽  
Patrick McKeon
Keyword(s):  
Monoamine Oxidase ◽  
Tricyclic Antidepressants ◽  
Monoamine Oxidase Inhibitor ◽  
Bipolar Affective Disorder ◽  
Oxidase Inhibitor ◽  
New Drugs ◽  
Mao Inhibitors ◽  
Mao Inhibitor ◽  
Relative Safety ◽  
Inhibitor Treatment

AbstractInterest in the monoamine oxidase (MAO) inhibitors has been revived over the past fifteen years since the publication of studies and reviews which argue their relative safety and efficacy in certain patient subgroups. The authors conclude that there is a continuing role for the MAO inhibitors in treating atypical depressive illness and panic disorders. Careful selection of patients to be commenced on MAO inhibitor treatment is advised. When prescribed alone or in combination with lithium there is evidence to support a usefulness for MAO inhibitors in depression resistant to the tricyclic antidepressants. Their efficacy in the depressed phase of bipolar affective disorder or in combination with the tricyclic antidepressants remains unproven. The risk of anaesthesia while a patient is receiving MAO inhibitor treatment may be less than heretofore believed. There is realistic hope of finding among the short-acting selective MAO inhibitors an effective antidepressant which is also free from tyramine related effects. With the increasing difficulties of evaluating new drugs on account of ethical and governmental constraints, it may however be some time before the preliminary hopeful findings can be substantiated in larger groups of patients.

Possible antidepressant/mania-inducing effects of methionine: a reappraisal of the effects of methionine in chronic psychosis using modern diagnostic criteria

1989 ◽  
Vol 4 (3) ◽  
pp. 175-181
Author(s):  
J.F. Lipinski ◽  
R.C. Alexander
Keyword(s):  
Monoamine Oxidase ◽  
Diagnostic Criteria ◽  
Monoamine Oxidase Inhibitor ◽  
Manic Episode ◽  
Oxidase Inhibitor ◽  
Descriptive Data ◽  
Antidepressant Effects ◽  
Chronic Psychosis

SummaryThe authors have reviewed 13 published studies on methionine administration, usually in combination with a monoamine oxidase inhibitor (MAOI), to chronically psychotic patients, using modern (DSM-III) diagnostic criteria. Four of these studies contained sufficient descriptive data to allow reappraisal of the effects. The results of the review suggest that a proportion of the patients experienced the induction of a manic episode/antidepressant effects rather than the reported worsening of schizophrenia while treated with a methionine-MAOI combination. It is suggested that these observations are consistent with recent findings that S-adenosyl-L-methionine (SAMe) has antidepressant and mania-inducing effects.

Sign in / Sign up

Export Citation Format

Share Document